Print pageHome » News: Pfizer Buys Back Massive, Dated Rouses Point Facility
News: Pfizer Buys Back Massive, Dated Rouses Point Facility
PharmaManufacturing.com
06/30/2011
Pfizer has announced that it will buy back the historic, one-million-square-foot manufacturing facility in Rouses Point, New York (a former Wyeth facility). For the past several years, the site had been leased to contract manufacturer Akrimax, who was not able to bring in significant new business due to the current economic conditions and glut of contract manufacturing capacity.
Pfizer spokesman Chris Loder says that the company will look for a new buyer and, if one is not found, "exit the facility" by the end of 2013. Local public radio station WAMC has an excellent podcast on the decision, including a conversation with Loder and opinions from the local chamber of commerce president who admits the site is “massive and dated” and will be hard for Pfizer to move, despite its excellent track record and skilled workforce. The mayor of Rouses Point says the news could have been worse, and Pfizer's reacquisition at least offers some hope of resurrecting business at the plant.
For some historical perspective, here's a 2008 article on Akrimax in Rouses Point based on our discussions with then-enthusiastic executives.
More News:
-
05/17/2013
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
-
05/16/2013
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
-
05/16/2013
$15 Billion Myland Offer Rejected By ActavisFrom Bloomberg.com
Actavis has rejected drugmaker Mylan Inc's cash-and-stock offer for $15 billion. They have decided to continue talks to take over Warner Chilcott Plc instead, sources have said.
-
05/15/2013
Rapid Micro Biosystems Offers Workshops at New European Headquarters in MunichFrom Rapid Micro Biosystems
Company hosts hands-on demonstrations of its Growth Direct System
-
05/13/2013
Amgen, Zhejiang Beta Pharma Form Joint VentureFrom FOX Business
Amgen will form a joint venture with Chinese pharma firm to bring its colon cancer drug Vectibix to the Chinese market
-
05/13/2013
Academic Tech Transfer Collaboration Required for Pharma R&D ModelFrom IT News Online
Pharma R&D Model Needs Academic Tech Transfer Collaboration for the Future of Drug Innovation Says New Report
-
05/09/2013
CEM Wins Solid-Phase Peptide Synthesis Patent DisputeFrom CEM
CEM's European Patent covering microwave assisted solid phase peptide synthesis has been upheld in an oral proceeding
-
05/08/2013
Biosimilars Market Prediction Up 20 Percent from 2012From Drug Store News
New report forecasts global $2.445 billion market this year
-
05/08/2013
Cholesterol Drugs Could Help Kidney Cancer SurvivalFrom HealthDay News
Study finds statin medications tied to lower death risk after nearly four years of follow-up
-
05/07/2013
Thermo Fisher Scientific Launches Online Configuration ToolFrom Thermo Fisher Scientific
iAutomate software reduces time needed for optimal system set-up design and provides accurate estimates
- All news »
Get Connected Now!
- Featured White Papers
Sponsored Links
